Mirabegron Avansor (Mirabegron)

Mirabegron selectively stimulates β3‑adrenergic receptors on the detrusor muscle of the bladder. This activation relaxes the smooth muscle during the storage phase, allowing the bladder to hold more urine and decreasing the frequency of sudden urges to void.

The appropriate dose of Mirabegron Avansor is determined by the prescribing healthcare professional based on individual patient factors such as age, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Mirabegron Avansor in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made together with a qualified healthcare provider.

To order Mirabegron Avansor, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different class (β3‑adrenergic agonist) than anticholinergic agents. While both aim to reduce bladder overactivity, mirabegron works by relaxing detrusor muscle via β3 receptors, often resulting in a lower incidence of dry mouth and constipation, which are common with anticholinergics.

Mirabegron Avansor should be stored at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture, and avoid exposure to direct sunlight or extreme heat to maintain potency.

Mirabegron Avansor is taken orally, usually once daily with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise instructed.

Serious risks, though uncommon, include acute urinary retention, severe hypertension, angioedema, myocardial infarction, and severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like sudden inability to urinate, chest pain, swelling of the face or throat, or rash.

Mirabegron Avansor is contraindicated in patients with known hypersensitivity to mirabegron or any of its excipients. Caution is advised for individuals with uncontrolled hypertension, severe renal impairment, or those taking strong CYP2D6 inhibitors or CYP3A4 inducers without appropriate dose adjustments.